HLA-A and COVID-19: Using predicted HLA-A*02:01−binding SARS-CoV-2−derived peptides from the S, N, M, and Polyprotein1ab (Orf1ab) proteins (SI Appendix, Table S3; based on two prediction algorithms: NetCTLpan and NetMHCpan; accessed 27 March 2020), PBMCs from five HLA-A*02:01+ COVID-19 convalescent individuals were expanded in vitro with a pool of 14 predicted A2/SARS-CoV-2 peptides for 10 d, then restimulated with individual peptides in an ICS assay to determine peptide immunogenicity.